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1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan; 2Department 
of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas; 3Department of Clinical Sciences, Touro University California College of Pharmacy, 
Vallejo, California; 4Department of Clinical Pharmacy, UCSF School of Pharmacy, San Francisco, California; 5Division of Infectious Diseases, Department of Medicine, School of Medicine, Wayne 
State University, Detroit, Michigan; 6Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan
Background. Data suggest that vancomycin + β-lactam combinations improve clearance of methicillin-resistant Staphylococcus 
aureus (MRSA) bloodstream infections (BSIs). However, it is unclear which specific β-lactams confer benefit. This analysis evaluates 
the impact of concomitant empiric cefepime on outcomes of MRSA BSIs treated with vancomycin.
Methods. Retrospective cohort study of adults with MRSA BSI from 2006 to 2017. Vancomycin + cefepime therapy was defined 
as ≥24 hours of cefepime during the first 72 hours of vancomycin. The primary outcome was microbiologic failure, defined as BSI 
duration ≥7 days and/or 60-day recurrence. Multivariable logistic regression was used to evaluate the association between vancomy-
cin + cefepime therapy and binary outcomes. Cause-specific and subdistribution hazard models were used to evaluate the associa-
tion between vancomycin + cefepime and BSI clearance.
Results. Three hundred fifty-eight patients were included, 129 vancomycin and 229 vancomycin + cefepime. Vancomycin + 
cefepime therapy was independently associated with reduced microbiologic failure (adjusted odds ratio [aOR], 0.488; 95% confi-
dence interval [CI], 0.271–0.741). This was driven by a reduction in the incidence of BSI durations ≥7 days (vancomycin + cefepime 
aOR, 0.354; 95% CI, 0.202–0.621). Vancomycin + cefepime had no association with 30-day mortality (aOR, 0.952; 95% CI, 0.435–
2.425). Vancomycin + cefepime was associated with faster BSI clearance in both cause-specific (HR, 1.408; 95% CI, 1.125–1.762) and 
subdistribution hazard models (HR, 1.264; 95% CI, 1.040–1.536).
Conclusions. Concomitant empiric cefepime improved MRSA BSI clearance and may be useful as the β-lactam component of 
synergistic vancomycin + β-lactam regimens when empiric or directed gram-negative coverage is desired.
Keywords. bacteremia; beta-lactam; combination therapy; MRSA; synergy.
Methicillin-resistant Staphylococcus aureus (MRSA) is a seri-
ous public health threat resulting in thousands of infections 
and deaths annually [1]. A  major contributor to the associ-
ated morbidity and mortality is MRSA bloodstream infection 
(BSI) [2, 3]. Vancomycin has been the treatment of choice 
for MRSA BSI for decades, but treatment failure rates are in 
excess of 30% [4–6]. Despite availability of newer alternative 
anti-MRSA treatment options, none have been shown to be 
conclusively superior to vancomycin for MRSA BSI [6–10]. 
Combination therapy, such as vancomycin plus an amino-
glycoside, has also been used in attempt to optimize efficacy. 
However, this approach fell out of favor due to increased risk 
of nephrotoxicity, coupled with lack of data to demonstrate 
improved treatment outcome [11].
The concept of combination therapy for MRSA BSI is being 
reexamined, as researchers and clinicians have begun to further 
explore previously identified synergy between glycopeptide and 
β-lactam antibiotics [12]. Synergy between vancomycin and sev-
eral β-lactams, including nafcillin, cefazolin, piperacillin/tazo-
bactam, cefepime, and ceftaroline, has been well documented 
in vitro and in vivo [13–17]. This synergy appears to translate to 
the clinical setting. A pilot randomized controlled trial of van-
comycin plus flucloxacillin vs vancomycin monotherapy demon-
strated shortened BSI duration in the combination group [18]. 
Observational studies of vancomycin given in combination with 
β-lactams empirically in patients ultimately found to have MRSA 
BSI also suggest improved microbiologic clearance [19, 20].
Although a vancomycin + β-lactam approach for MRSA BSI 
shows promise, challenges remain before it can be translated 
into practice. The majority of the clinical evidence involves an 
amalgamation of different β-lactam antibiotics [19, 20]. This 
makes it difficult to discern which specific β-lactams provide 
clinical benefit and which are best suited for this purpose. This 
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is particularly true in the United States, where flucloxacillin, the 
single agent with the strongest clinical evidence at the present 
time, is not commercially available [18]. Although ongoing 
studies may address this need by studying specific narrow-spec-
trum β-lactams, clinical data evaluating broad-spectrum β-lac-
tams will still be needed [21]. Such data would be crucial in 
adopting a vancomycin + β-lactam approach to inform empiric 
prescribing before MRSA is identified  and directed therapy 
when patients require continued gram-negative coverage. Given 
the frequency with which cefepime is used concomitantly with 
vancomycin for empiric antibiotic therapy for suspected antibi-
otic-resistant infections and the in vitro synergy between these 
2 agents, the objective of this analysis was to evaluate the impact 
of concomitant empiric cefepime on patient outcomes of MRSA 
BSI treated with vancomycin.
METHODS
Study Design and Population
This was a retrospective, observational cohort study of adult 
patients with MRSA BSI from 2006 to 2017 at the Detroit 
Medical Center (DMC), an eight hospital healthcare system 
in Southeast Michigan. Patients aged ≥18  years with ≥1 pos-
itive blood culture for MRSA initially treated with ≥72 hours 
of vancomycin were eligible for inclusion [22]. Patients who 
received ≥24 hours of concomitant MRSA-active therapy or 
a β-lactam other than cefepime during the initial 72 hours of 
vancomycin therapy were excluded. Patients without follow-up 
blood cultures and those with repeat MRSA BSI episodes were 
also excluded. Patients who received ≥24 hours of concomitant 
cefepime during the initial 72 hours of vancomycin therapy were 
considered to have received vancomycin + cefepime. Patients 
who received <24 hours of cefepime were considered to have 
received vancomycin monotherapy. This study was approved 
by the DMC Research Review Committee and the institutional 
review board at Wayne State University (WSU), and a waiver of 
informed consent was granted.
Patient Data Elements and Collection
Methicillin-resistant Staphylococcus aureus BSIs for inclusion 
were identified through a list of positive MRSA blood cultures 
at the DMC during the study period. Patient data were extracted 
from the medical record by trained reviewers using a struc-
tured data collection form within the Research Electronic Data 
Capture (REDCap; Vanderbilt University) data capture tool 
hosted at WSU [23]. Data elements included demographics, 
medical history, comorbid conditions, antibiotic therapy and 
associated laboratory parameters, infectious diseases consult, 
and pursuit of source control. The degree of patient comorbidity 
was quantified using the Charlson comorbidity index [24]. 
Severity of illness was quantified using the Acute Physiology 
and Chronic Health Evaluation II (APACHE II) score using the 
worst physiological parameters within 24 hours of index MRSA 
blood culture [25]. The source of the MRSA BSI was based on 
the treating physician’s notes and available clinical/diagnostic 
data. Microbiologic data including antibiotic susceptibilities by 
Microscan, Phoenix, and/or Etest were collected from the med-
ical record.
Outcomes
The primary outcome was microbiologic failure, defined as a BSI 
duration ≥7 days and/or MRSA BSI recurrence within 60 days 
of the end of MRSA BSI therapy. Secondary outcomes included 
each individual component of microbiologic failure, mortality 
from any cause within 30 days of index MRSA blood culture, 
time to MRSA BSI clearance in days, and hospital-length of stay 
(LOS) post–MRSA BSI onset in days.
Data Analysis
The primary analysis focused on examining the association 
between concomitant vancomycin + cefepime therapy and 
microbiologic failure. Bivariate analysis was conducted com-
paring covariates between patients who did and did not experi-
ence microbiologic failure. Categorical variables were compared 
between groups using the χ2 or Fisher exact test, whereas contin-
uous variables were compared using the Student t test or Mann 
Whitney U test. The independent association between concom-
itant vancomycin + cefepime therapy and microbiologic fail-
ure was then examined using multivariable logistic regression. 
Vancomycin + cefepime therapy, along with all the variables asso-
ciated with microbiologic failure at a P value <.2 in bivariate anal-
ysis with biologic plausibility, were entered into logistic regression 
models simultaneously and removed in a backward, stepwise fash-
ion. Covariates were retained in the final model if the P value for 
the likelihood ratio test for their removal was <.1. Because van-
comycin + cefepime was the exposure of interest, it was forced to 
remain in the final step of the regression models even if no sta-
tistical association was observed. Model fit was assessed with the 
Hosmer-Lemeshow goodness-of-fit test; models with a nonsignif-
icant result were considered adequate. Multicollinearity of can-
didate regression models was assessed via the variance inflation 
factor, with values between 1 and 5 considered acceptable.
Given the imbalance in the proportion of patients with an 
endovascular BSI source between treatment groups and the 
well-documented association between endovascular sources 
and prolonged, recurrent BSI, a secondary post hoc matched 
analysis was conducted to further examine the association 
between vancomycin + cefepime therapy and microbiologic 
failure. Patients were matched 1:1 on endovascular source, and 
conditional logistic regression was conducted on the resulting 
matched data set as described above for the primary analysis.
Additional secondary analyses were conducted to examine 
the association between vancomycin + cefepime therapy and the 
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between vancomycin + cefepime therapy and secondary out-
comes in bivariate analysis were examined further through 
multivariable analysis using model-building strategies congru-
ent with those explained above for the primary analysis. The 
independent association between vancomycin + cefepime ther-
apy and BSI clearance was evaluated using both a cause-specific 
proportional hazard model (patients experiencing mortality 
before BSI clearance were censored) and a subdistribution haz-
ards model (simultaneous model of survival and BSI duration) 
to account for the competing risks of death and BSI clearance 
[26].
All statistical tests were 2-sided; P values ≤.05 were consid-
ered statistically significant. Analyses were performed using 
SPSS Statistics, IBM SPSS software, version 25.0 (IBM Corp., 
Armonk, NY), and SAS, version 9.4 (Cary, NC).
RESULTS
A total of 358 patients were included. A  full description of 
demographics, clinical characteristics, and outcomes of the 
cohort is available in Supplementary Table 1. The cohort was 
predominantly African American (79.6%), majority male 
(64.8%), and had a median (interquartile range [IQR]) age of 60 
(52–69) years. Common comorbidities were diabetes (38.0%), 
moderate/severe renal disease (35.5%), chronic hemodialysis 
(25.4%), heart failure (23.5%), intravenous drug use (15.1%), 
and liver disease (15.6%). The median (IQR) Charlson comor-
bidity index and APACHE II scores were 3 (1–5) and 18 (11–
24), respectively. The most common MRSA BSI sources were 
endovascular (23.5%), lower respiratory tract (21.5%), skin 
and soft tissue (21.2%), and intravenous catheter (20.4%). The 
median (IQR) duration of vancomycin therapy was 5 (4–9) 
days. The majority of patients (79.5%) had their vancomycin 
therapy dosed and monitored to a trough concentration target 
range of 15–20 mg/L, whereas the remaining had their vanco-
mycin therapy dosed and monitored to an AUC of 400–600 
mg*h/L [27, 28]. Two hundred twenty-nine patients (64.0%) 
received concomitant cefepime therapy with a median (IQR) 
duration of 3 (2–4) days. The most common cefepime dose 
and interval were 1000 mg (52.4%) and every 8 hours (41.5%), 
respectively. Microbiologic failure was observed in 107 patients 
(29.9%), with 83 (23.3%) having a BSI duration ≥7 days. Thirty-
day mortality was observed in 57 (15.9%) patients.
Bivariate comparisons between patients receiving vancomy-
cin or vancomycin + cefepime are displayed in Table 1. Patients 
receiving vancomycin + cefepime were significantly older, had a 
higher proportion of baseline acute kidney injury, and had sig-
nificantly higher APACHE II scores. Although select individual 
comorbid conditions differed between groups, no difference in 
Charlson comorbidity index was observed. Patients receiving 
vancomycin + cefepime were more likely to have been admit-
ted from a nursing facility or have a polymicrobial bloodstream 
infection. Endovascular MRSA BSI source, including endocar-
ditis, and lower respiratory tract source were more common 
among vancomycin + cefepime patients, whereas skin and soft 
tissue and bone/joint source were more common among van-
comycin monotherapy patients. Patients in the vancomycin + 
cefepime group were more likely to have AUC-guided vanco-
mycin therapy. Microbiologic failure was significantly more 
common among vancomycin monotherapy patients (Figure 
1). This difference was primarily driven by a greater incidence 
of BSI durations ≥7  days in the vancomycin monotherapy 
group. No difference in the incidence of 60-day recurrence was 
observed. Thirty-day mortality was significantly more common 
among vancomycin + cefepime patients. No difference in safety 
outcomes, including vancomycin-associated nephrotoxicity, 
neurotoxicity, or CDI, was observed between treatment groups 
(Table 1).
The results of logistic regression analysis for independent 
predictors of microbiologic failure are displayed in Table 2. 
Accounting for endovascular BSI source, African American 
race, and unknown BSI source, vancomycin + cefepime therapy 
was independently associated with less frequent microbiologic 
failure (adjusted odds ratio [aOR], 0.488; 95% confidence in-
terval [CI], 0.271–0.741). Results were consistent in post hoc 
analysis in the cohort of 258 patients (129 vancomycin, 129 van-
comycin + cefepime) who were matched on endovascular BSI 
source (Supplementary Table 2). Patients receiving vancomycin 
+ cefepime were significantly less likely to experience microbio-
logic failure (aOR, 0.517; 95% CI, 0.298–0.899).
Because the difference in microbiologic failure was primar-
ily due to BSI duration ≥7  days, logistic regression analysis 
was also performed for this outcome (Supplementary Table 3). 
Accounting for endovascular source, vancomycin + cefepime 
therapy was associated with reduced incidence of BSI duration 
≥7 days (aOR, 0.354; 95% CI, 0.202–0.621). The results of logis-
tic regression analysis for independent predictors of mortality 
are displayed in Table 3. Accounting for lower respiratory tract 
BSI source, endocarditis source, APACHE II score, age, and ID 
consult, vancomycin + cefepime therapy was not associated 
with 30-day mortality (aOR, 0.952; 95% CI, 0.435–2.425).
The results of proportional hazards regression models for BSI 
clearance are shown in Table 4. Accounting for endovascular 
source, patients receiving vancomycin + cefepime were more 
likely to experience BSI clearance (HR, 1.408; 95% CI, 1.125–
1.762). Similar results were observed using a subdistribution 
hazard model (HR, 1.264; 95% CI, 1.040–1.536).
DISCUSSION
This study sought to examine the impact of concomitant 
cefepime on the outcomes of patients with MRSA BSIs initially 
treated with vancomycin. The results suggest that concomi-
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Table 1. Bivariate Comparisons of Demographics, Clinical Characteristics, and Outcomes Between Patients Receiving Vancomycin or Vancomycin + 
Cefepime
Covariate Vancomycina (n = 129) Vancomycin + Cefepimea (n = 229) P Value
Demographics
Age, y 56 (48–66.5) 61 (53.5–71) .001
Male 86 (66.7) 146 (63.8) .580
Race   .548
 African American 105 (81.4) 180 (78.6)  
 Caucasian 20 (15.5) 45 (19.7)  
 Hispanic 2 (1.6) 3 (1.3)  
 Other/unknown 2 (1.6) 1 (0.4)  
Comorbidities & medical history
Myocardial infarction 4 (3.1) 20 (8.7) .047
Heart failure 26 (20.2) 58 (25.3) .268
Peripheral vascular disease 27 (20.9) 43 (18.8) .622
Cerebrovascular disease 18 (14.0) 45 (19.7) .174
Dementia 8 (6.2) 36 (15.7) .008
Chronic pulmonary disease 25 (19.4) 66 (28.8) .049
 Chronic obstructive pulmonary disease 21 (16.3) 59 (25.8) .039
 Asthma 5 (3.9) 12 (5.2) .560
Connective tissue disease 19 (14.7) 24 (10.5) .235
Peptic ulcer disease 2 (1.6) 5 (2.2) 1.000
Liver disease 25 (19.4) 31 (13.5) .144
 Mildb 23 (17.8) 27 (11.8) .114
 Moderate/severec 2 (1.6) 4 (1.7) 1.000
Diabetes 47 (36.6) 89 (38.9) .649
 With end-organ damage 37 (28.7) 56 (24.5) .381
Hemiplegia 3 (2.3) 5 (2.2) 1.000
Moderate/severe renal diseased 41 (31.8) 86 (37.6) .273
 Chronic hemodialysis 29 (22.5) 62 (27.1) .338
Solid tumor without metastasis 2 (1.6) 5 (2.2) 1.000
Leukemia 0 0 —
Lymphoma 0 0 —
Metastatic solid tumor 5 (3.9) 8 (3.5) 1.000
HIV 5 (3.9) 7 (3.1) .679
AIDS 3 (2.3) 2 (0.9) .261
Charlson comorbidity index 2 (1–5) 3 (1–5) .303
Intravenous drug use 25 (19.4) 29 (12.7) .088
Prior hospitalization (90 d) 48 (37.2) 97 (42.4) .341
Prior IV vancomycin (90 d) 31 (24.0) 51 (22.3) .704
Prior MRSA infection (1 y) 26 (20.2) 28 (12.2) .044
Clinical data
Admitted from:   .011
 Home 98 (76.0) 146 (63.8) .017
 Nursing facility 20 (15.5) 68 (29.7) .003
 Transferred from another hospital 11 (8.5) 15 (6.6) .489
Weight, kg 75 (66.8–87.5) 76.9 (65.1–91.6) .541
Creatinine clearance,e,f mL/min 72.9 (49.2–98.1) 56.5 (33.2–89.2) .009
Acute kidney injuryf 34 (26.4) 84 (36.7) .046
APACHE II scoref 13 (8–19) 20 (15–27) <.001
Neutropeniaf 0 1 (0.4) 1.000
Infection data
Vancomycin MIC,g mg/L   .834
 2 50 (38.8) 96 (41.9)  
 1 78 (60.5) 131 (57.2)  
 ≤0.5 1 (0.8) 2 (0.9)  
Polymicrobial BSI 0 16 (7.0) .001
BSI source
Endovascular 20 (15.5) 64 (27.9) .008
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of patients experiencing BSI durations ≥7  days. Although a 
larger proportion of patients in the vancomycin + cefepime 
group experienced 30-day mortality, this difference did not 
persist after accounting for clinical factors influencing mor-
tality risk, such as age, infection source, and severity of illness. 
Care was also taken to ensure that the reduced BSI duration in 
Covariate Vancomycina (n = 129) Vancomycin + Cefepimea (n = 229) P Value
 Other endovascular 0 11 (4.8) .009
Intra-abdominal 0 1 (0.4) 1.000
Lower respiratory tract 6 (4.7) 72 (31.4) <.001
Bone/joint 30 (23.3) 23 (10.0) .001
Invasive prosthetic device 7 (5.4) 13 (5.7) .921
Skin/soft tissue 39 (30.2) 37 (16.2) .002
CNS abscess 5 (3.9) 4 (1.7) .293
Intravenous catheter 24 (18.6) 49 (21.4) .529
Urinary 3 (2.3) 6 (2.6) 1.000
Unknown 10 (7.8) 23 (10.0) .472
Treatment data
Infectious diseases consult 103 (79.8) 197 (86.0) .128
Source control pursued 57 (44.2) 80 (34.9) .084
Vancomycin TDM target   .015
 Trough concentration 15–20 mg/L 115 (89.1) 181 (79.0)  
 AUC 400–600 mg*h/L 14 (10.9) 48 (21.0)  
Cefepime dose, mg   —
 1000 — 120 (52.4)  
 2000  109 (47.6)  
Cefepime dose interval    
 Every 6 h  2 (0.9)  
 Every 8 h  95 (41.5)  
 Every 12 h — 52 (22.7) —
 Every 24 h  62 (27.1)  
 Post-hemodialysis  18 (7.9)  
Inpatient vancomycin duration, d 6 (4–10) 5 (4–9) .071
Inpatient cefepime duration (n = 229), d — 3 (2–4) —
Switched to daptomycin 36 (27.9) 70 (30.6) .597
Switched to ceftaroline 8 (6.2) 25 (10.9) .139
Switched to linezolid 8 (6.2) 13 (5.7) .839
Switched to alternative anti-MRSA therapy before day 5 8 (6.2) 22 (9.6) .264
Total duration inpatient antibiotics, d 9 (5–18) 9 (6–13.5) .335
Outcomes
Microbiologic failure 49 (38.0) 58 (25.3) .012
 BSI duration ≥7 d 40 (31.0) 43 (18.8) .008
 60-d MRSA BSI recurrence 15 (11.6) 19 (8.3) .302
30-d mortality 10 (7.8) 47 (20.5) .002
BSI duration, d 4 (3–7) 3 (2–5.5) .003
LOS post–BSI onset, d 13 (8–21) 11 (7–17) .064
Vancomycin-associated nephrotoxicityh 7 (5.4) 12 (5.2) .940
Neurotoxicity attributed to antibiotic(s)i 0 1 (0.4) 1.000
Clostridium difficile infectionj 2 (1.6) 8 (3.5) .341
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; AUC, area under the concentration time curve; BSI, bloodstream infection; CNS, central nervous system; IV, 
intravenous; LOS, length of stay; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; TDM, therapeutic drug monitoring. 
aData presented as number (percentage) or median (interquartile range).
bMild liver disease defined as chronic hepatitis without cirrhosis.
cSevere liver disease defined as portal hypertension or cirrhosis.
dModerate/severe renal disease defined as chronic kidney disease stage 3 or greater or receiving chronic dialysis.
eCalculated using the Cockroft-Gault formula using actual body weight for body mass index <30 and adjusted body weight for body mass index >30.
fAt time of index MRSA blood culture.
gAutomated susceptibility testing performed by Microscan or Phoenix.
hVancomycin-associated nephrotoxicity defined as a serum creatinine increase of 0.5 mg/L and 50% from baseline on 2 consecutive measurements from initial vancomycin dose to 72 
hours after the last dose.
iNeurotoxicity defined as seizure, encephalopathy, or altered mental status specifically attributed to vancomycin and/or cefepime by treating physician(s).
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the vancomycin + cefepime group was not due to the differen-
tial mortality in the combination group through cause-specific 
and subdistribution hazard models designed to account for this 
competing risk.
These data contribute to a growing body of clinical evidence 
that receipt of concomitant vancomycin and β-lactam antibiot-
ics in patients with MRSA BSI improves BSI clearance and may 
improve microbiologic outcome. This includes a pilot random-
ized controlled trial of vancomycin + flucloxacillin and multiple 
small observational cohort studies of vancomycin in combina-
tion with various β-lactams [18–20]. Like the currently published 
observational studies, the β-lactam combination therapy in this 
present study was not given with the intent of providing synergy 
against MRSA but to provide broad-spectrum coverage. Although 
this diminishes the ability to measure the potential impact of 
a purposeful vancomycin + β-lactam combination therapy 
approach, it provides evidence that the in vitro synergy between 
vancomycin and β-lactams translates into patients. The present 
study advances knowledge of vancomycin + β-lactam combina-
tion therapy in 2 important ways. First, it focuses on cefepime, 
whereas previous studies included a heterogenous group of β-lac-
tams, making it difficult to surmise which β-lactams confer bene-
fit. Second, it accounts for the differential mortality risk typically 
seen in combination patients, which could otherwise be posited 
as a potential explanation for the observed shortened BSI dura-
tion with combination therapy (i.e., combination patients may 
have had shorter BSI durations because they were more likely to 
die before clearance of BSI could occur or be confirmed).
Although vancomycin + cefepime combination therapy 
improved MRSA BSI clearance, this does not indicate that 
cefepime should be the β-lactam of choice for directed MRSA 
BSI combination regimens. In vitro data coupled with pilot data 
of flucloxacillin suggest that antistaphylococcal penicillins and 
cefazolin can likely be used with vancomycin for directed MRSA 
BSI synergy [14–16, 18]. This would limit the potential unnec-
essary collateral damage that may come with the expanded 
gram-negative spectrum of cefepime. However, if a vancomycin 
+ β-lactam approach is to be implemented, cefepime may be 
an ideal candidate for empiric therapy, provided that the insti-
tution’s gram-negative antibiogram permits. Because it is usu-
ally 24 hours before staphylococci are identified and often an 
additional 24–48 hours to detect methicillin resistance, MRSA-
directed combination therapy may be delayed. Considering the 
importance of the initial 48 hours of therapy in Staphylococcus 
aureus bloodstream infection mortality, it would be ideal to 
provide empiric synergy [29–31]. In situations where empiric 
vancomycin + cefepime is already warranted, cefepime would 
satisfy the synergistic β-lactam role in patients ultimately found 
to have MRSA BSI. Upon isolation of Staphylococcus aureus or 
MRSA, cefepime could be switched to antistaphylococcal pen-
icillin or cefazolin. If ongoing gram-negative coverage were 
required, synergy could be provided by continuing cefepime 
without the need to add a second β-lactam.
There are a number of considerations to bear in mind when 
interpreting these findings. Most importantly, the intention of 
the concomitant cefepime therapy was to provide either empiric 
or directed coverage of gram-negative organisms rather than 
synergy against MRSA. As such, it is unclear what the impact of 
purposeful vancomycin + β-lactam therapy would have been. 
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Figure 1. Comparison of efficacy outcomes between patients receiving vanco-
mycin or vancomycin + cefepime. Abbreviation: BSI, bloodstream infection.
Table 2. Multivariable Logistic Regression for Factors Independently Associated With Microbiologic Failure
Variable OR (95% CI) Adjusted OR (95% CI)
Vancomycin + cefepime 0.554 (0.348–0.881) 0.488 (0.271–0.741)
Endovascular source 3.215 (1.930–5.356) 3.321 (1.925–5.730)
African American 2.542 (1.306–4.948) 2.121 (1.064–4.228)
Unknown source 0.297 (0.102–0.868) 0.360 (0.118–1.102)
Invasive prosthetic device source 2.004 (0.805–4.986) —
Intravenous drug use 1.943 (1.072–3.523) —
Bone/joint source 1.519 (0.826–2.791) —
Chronic hemodialysis 1.484 (0.896–2.457) —
Acute kidney injury 1.404 (0.875–2.253) —
Lower respiratory tract source 0.487 (0.263–0.901) —
Hosmer-Lemeshow goodness-of-fit test P = .835; variance inflation factor 1–5 for all variables included at model entry.
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the treatment groups, with vancomycin + cefepime patients 
having a substantially higher baseline mortality risk. Although 
various statistical techniques were used to account for this, the 
extraordinarily disproportionate mortality risk between treat-
ment groups may have precluded our ability to observe a poten-
tial mortality benefit with combination therapy. Although no 
studies to date have demonstrated improvement in hard out-
comes with vancomycin + β-lactam combination therapy for 
MRSA BSI, the known link between prolonged BSI and mortal-
ity make it reasonable to hypothesize that there is some benefit 
to a combination approach [32, 33]. Whether the effect size of 
this benefit is large enough to be feasibly measured in a clinical 
trial or is clinically meaningful is unknown. We did not observe 
increased adverse drug reactions in the combination group to 
indicate that the risk of combination may outweigh the poten-
tial benefit. However, it should be noted that this analysis was 
not specifically designed or powered to fully evaluate safety.
It is also important to note that the study population was 
derived from a single health system in Southeastern Michigan, 
which may limit the external generalizability of the findings. In 
particular, the MRSA strain epidemiology and practice pattern 
may differ from other sites, and it is unclear how this could have 
influenced the findings. The automated susceptibility testing 
MIC results from the hospital clinical microbiology labora-
tory did not indicate a difference in vancomycin susceptibility 
between the treatment groups. However, the Microscan plat-
form used for the majority of the study period is known to con-
sistently overcall vancomycin MIC relative to nonautomated 
broth microdiluton [34, 35]. This likely explains the large pro-
portion of isolates with a vancomycin MIC of 2 mg/L in this 
study; this limited our ability to fully control for phenotype. 
Finally, because only a small proportion of the patients were 
monitored by vancomycin AUC, we were unable to control for 
vancomycin exposure [36]. Given the fact that AUC-guided 
dosing was more common in the vancomycin + cefepime group 
and is associated with reduced vancomycin dose and exposure, 
it is implausible that AUC-guided dosing would explain the 
improved BSI clearance observed in the combination patients 
[28, 37].
In conclusion, cefepime given concomitantly during the 
first 72 hours of vancomycin therapy was associated with 
improved  MRSA BSI clearance. Although the cefepime was not 
given with the intention of providing synergy against MRSA, 
these data lend further support to the notion that vancomycin 
+ β-lactam therapy may be a potential avenue to improve treat-
ment outcomes of MRSA BSI. Although further study evaluat-
ing the impact of purposeful vancomycin + β-lactam therapy 
for MRSA BSI is needed before widespread clinical implemen-
tation, this study suggests that cefepime can be used as the β-lac-
tam component of synergistic vancomycin + β-lactam regimens 
when empiric or directed gram-negative coverage is desired.
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